Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs IONQ Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while IONQ Inc trades at $41.95 (market cap $16.00B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.5× IONQ Inc's market cap, and IONQ Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | IONQ | |
|---|---|---|
Market Cap | $39.89B | $16.00B |
Sector | Health | Technology |
52-Week High | $491.22 | $82.09 |
52-Week Low | $278.09 | $26.59 |
Enterprise Value | $38.15B | $14.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IONQ trades at $42.86, down 4.27% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong revenue growth with 2025 revenue of $130.02M and a net loss of $510.38M, though profitability is projected for 2026. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a Q3 2025 miss, while analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains speculative with high valuation multiples (P/E 109.9, P/S 72.37) reflecting growth expectations in quantum computing. Key risks include cash burn and competitive pressures, but institutional sentiment is supported by a $73.75 price target and strong liquidity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
